Design and development of nanoproteomics strategies for biomarker identification in cerebrospinal fluid of leptomeningeal disease, using as model lymphoma non-Hodgkin B.

The early diagnosis of leptomeningeal disease is a challenge because it is an asymptomatic pathology in the early stages. Hence, it is highly relevant to identify a panel of biomarkers to help in the diagnosis and/or prognostic. For this purpose, we have explored a multipronged proteomics approaches, in cerebrospinal fluid, to determine a potential panel of biomarkers in cerebrospinal fluid. Thus, a systematic and exhaustive characterization of more than 347 CSF samples have been performed by an integrated LC-MS/MS (n 20) and functional proteomics (n 347) analysis to establish protein profiles which has been useful to develop a panel of biomarkers validated by in silico approaches.

软脑膜疾病（leptomeningeal disease）的早期诊断颇具临床挑战，因其在病程早期呈现无症状的病理状态。因此，筛选可用于辅助诊断和/或预后评估的生物标志物（biomarker）组群具有重要研究与临床价值。为此，本研究针对脑脊液（cerebrospinal fluid, CSF）采用多维度蛋白质组学策略开展探索，以期筛选出潜在的脑脊液生物标志物组群。综上，本研究通过整合液相色谱-串联质谱（liquid chromatography-tandem mass spectrometry, LC-MS/MS，n=20）与功能蛋白质组学（n=347）分析技术，对逾347例脑脊液样本完成了系统且详尽的表征，进而构建了蛋白质表达谱；该谱图可用于开发经计算机模拟（in silico）方法验证的生物标志物组群。